Indivior said on Friday its U.S. subsidiary has filed patent lawsuits against firms seeking approval for generic versions of its opioid addiction treatment Suboxone, which generates 80 percent of Indivior`s revenue.
The lawsuits were filed against Dr. Reddy`s, Allergan Plc`s Actavis Laboratories, Endo International`s Par Pharmaceutical, Alvogen Pharma US, Teva Pharmaceutical Industries and Mylan NV.
The lawsuits allege that these companies have infringed a patent that relates to an oral film containing buprenorphine and naloxone, the London-listed drugmaker said in a statement.
Indivior has already been involved in patent infringement litigations with the same companies over other patents related to the Suboxone film.
(This article has not been edited by Zeebiz editorial team and is auto-generated from an agency feed.)
Get Latest Business News, Stock Market Updates and Videos; Check your tax outgo through Income Tax Calculator and save money through our Personal Finance coverage. Check Business Breaking News Live on Zee Business Twitter and Facebook. Subscribe on YouTube.